# Safety and Efficacy of Asfotase Alfa in Patients With Hypophosphatasia (HPP)

> **NCT02456038** · PHASE2 · COMPLETED · sponsor: **Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan** · enrollment: 13 (actual)

## Conditions studied

- Hypophosphatasia

## Interventions

- **DRUG:** Asfotase Alfa (ALXN1215)

## Key facts

- **NCT ID:** NCT02456038
- **Lead sponsor:** Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2016-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02456038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02456038, "Safety and Efficacy of Asfotase Alfa in Patients With Hypophosphatasia (HPP)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02456038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*